Target intelligence / Profile preview

Krait venom neurotoxin

Molecular classification
Other (toxin), Protein toxin, Three-finger toxin (for α- and κ-bungarotoxins), Secretory phospholipase A2 (for β-bungarotoxin)
01

Overview

Krait venom neurotoxins are a family of protein toxins found in the venom of kraits (Bungarus species), highly venomous snakes in the family Elapidae[4]. Notable types include α-bungarotoxin, κ-bungarotoxin (both "three-finger toxins" acting primarily on postsynaptic nicotinic acetylcholine receptors), and β-bungarotoxin (a heterodimeric toxin of phospholipase A2 and a Kunitz-type inhibitor, acting presynaptically)[1][4]. α- and κ-bungarotoxins bind to nAChRs, blocking synaptic transmission at the neuromuscular junction and within the nervous system; β-bungarotoxin targets voltage-sensitive potassium channels and disrupts acetylcholine release from presynaptic terminals[4]. These neurotoxins are the main drivers of the rapid-onset paralysis and potentially fatal respiratory effects observed in krait envenomation[1]. Their structure, actions, and ability to specifically affect neurotransmission at both muscular and neuronal synapses have made them important research tools in neurobiology but they are not considered traditional drug targets themselves—rather, they are the "active components" of envenomation for which antivenoms are developed[4][5].

Other names
Krait venom neurotoxinsBungarotoxinsα-bungarotoxinβ-bungarotoxinκ-bungarotoxin
02

Mechanism of action

Postsynaptic antagonism of nicotinic acetylcholine receptor (α-bungarotoxin, κ-bungarotoxin), Presynaptic inhibition of acetylcholine release (β-bungarotoxin via phospholipase A2 activity and binding to potassium channels)

03

Biological functions

Neurotransmission inhibitionBlockade of nicotinic acetylcholine receptorInhibition of acetylcholine release (presynaptic and postsynaptic effects)Modulation of voltage-gated potassium channels
04

Disease associations

Neurotoxic envenomationParalysisOther (no direct link to cancer, inflammation, or other chronic diseases)
05

Safety considerations

High lethalityRespiratory paralysisRapid onset of neurotoxic symptomsAntivenom must be administered early; risk of permanent neurological damage if not treated promptly
06

Interacting drugs

Antivenoms (e.g., anti-bungarotoxin and polyvalent antivenoms used for snakebite treatment)

1 more in the full profile.

Beyond the preview

Go deeper on Krait venom neurotoxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Krait venom neurotoxin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call